Drugs / MPB-2043
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06540443 | Dec 2024 → Jun 2026 overdue | head and neck squamous cell carcinoma, metastatic malignant neoplasm in the lymph nodes | MegaPro Biomedical Co. Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MPB-2043 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06540443 ↗ |
| Route | Intravenous | “IV-infused MPB-2043 for 1 hour” NCT06540443 ↗ |